Zetagen’s multi-patented, ZetaMet™ technology is a first-of-its kind molecular pathway designed to suspend cancer, inhibit pain, and regenerate bone. Our goal is to help the hundreds of thousands of people diagnosed with metastatic bone cancers and millions of people needing osteologic intervention.
Zetagen is focused on the 330,000 people in the United States and more globally, annually living with some form of bone metastases. We have created a series of novel therapies which address metastatic cancers at progressive stages. Our therapies are designed to suspend cancer, inhibit pain, and regenerate bone. These technologies from Zetagen are adjunctive to other cancer treatments and can be administered when the lesion is first detected via a minimally invasive out-patient procedure. Pre-clinical studies have shown the potential to reduce lesion size by 200% and improve mortality rates of 250%.
The U.S Food and Drug Administration (FDA) has recognized Zetagen’s discoveries with multiple Breakthrough Device Designations. Zetagen discovered and patented the first-of-its kind molecular pathway designed to suspend cancer, inhibit pain, and regenerate bone. The small molecule has been approved by the FDA since 1971. Our research scientists have discovered an entirely new pathway for this established molecule which, if proven successful in human clinical trials, could create a new treatment paradigm for patients living with metastatic bone lesions and other osteologic conditions.
